Azitra, Inc. to Present at 2026 BIO International Convention
Rhea-AI Summary
Azitra (NYSE American: AZTR) will present at the 2026 BIO International Convention in San Diego. Cofounder and COO Travis Whitfill, Ph.D., MPH will speak on June 23, 2026, at 4:45 PM PT.
The presentation will cover pipeline progress, including ATR-12 and ATR-04 programs, and a new filaggrin-based protein and peptide initiative for cosmetic and cosmeceutical markets.
Positive
- None.
Negative
- None.
News Market Reaction – AZTR
In the Jun 17 session, AZTR gained 10.27%, reflecting a significant positive market reaction. Argus tracked a peak move of +151.9% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 163.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | Annual meeting adjourned | Negative | -3.2% | Adjourned annual meeting due to lack of quorum, reconvened date set. |
| May 27 | Meeting delay notice | Neutral | -0.6% | Planned adjournment of annual meeting to allow more proxy voting time. |
| May 13 | Q1 results update | Neutral | -1.5% | Reported Q1 2026 results and business updates in precision dermatology. |
| May 06 | Patent issuance | Positive | -0.5% | New U.S. patent protecting ATR-12 compositions and Netherton treatment methods. |
| Apr 28 | ASGCT poster data | Positive | +11.1% | Preclinical ATR-01 data for ichthyosis vulgaris presented at ASGCT 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent AZTR news often saw modest downside or mixed reactions, with a single strong gain on positive scientific data.
Over the last few months, AZTR has reported governance and financing steps alongside pipeline progress. An April 28 poster on ATR-01 at ASGCT, showing encouraging preclinical data, corresponded with a 11.08% gain. By contrast, patent protection for ATR-12 on May 6 and Q1 2026 updates on May 13 saw only slight declines. Multiple announcements around the 2026 annual meeting in late May and early June coincided with small negative moves. Today’s convention presentation continues the theme of highlighting its dermatology pipeline and cosmeceutical initiatives.
Key Terms
phase 1b medical
fast track designation regulatory
egfr inhibitor medical
live biotherapeutic products medical
artificial intelligence technical
machine learning technical
netherton syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will highlight recent updates and progress in Azitra's pipeline, including the launch of an innovative protein and peptide program for the cosmetic and cosmeceutical markets leveraging proprietary filaggrin technologies.
Presentation Details:
Event: | 2026 BIO International Convention |
Date and Time: | Tuesday, June 23 at 4:45 PM PT |
Location: | |
Presenter: | Travis Whitfill, Ph.D. MPH, Cofounder and Chief Operating Officer |
During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. Azitra is also developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market. The new initiative is the first amongst others, which aims to leverage Azitra's microbial genetic engineering platform to manufacture innovative proteins and peptides for the cosmetic and research markets. For more information, please visit https://azitrainc.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our provision of initial safety data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies, including our cosmeceutical strategy.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the timing of clinical trials and their results; we may experience delays in the provision of initial safety data and topline results for ATR-12 and ATR-04 and, if we do, such data and results may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on February 27, 2026 and our quarterly report on Form 10-Q filed on May 12, 2026 with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
231-632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-2026-bio-international-convention-302802364.html
SOURCE Azitra, Inc.